logo
Plus   Neg
Share
Email

HanesBrands Reiterates FY19 Outlook - Quick Facts

While reporting financial results for the first quarter, HanesBrands, inc. (HBI) on Thursday reiterated its full-year 2019 financial guidance and also provided outlook for the second quarter.

For fiscal 2019, the company continues to project earnings in a range of $1.59 to $1.67 per share, adjusted earnings in a range of $1.72 to $1.80 per share, and net sales between $6.885 billion and $6.985 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.76 per share on revenues of $6.91 billion for the year. Analysts' estimates typically exclude special items.

For the second quarter, the company expects earnings in a range of $0.40 to $0.42 per share, adjusted earnings in a range of $0.43 to $0.45 per share, and net sales between $1.735 billion and $1.765 billion. Analysts expect quarterly earnings of $0.46 per share on sales of $1.75 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chipotle Mexican Grill Inc. is introducing a new protein to its menu, Carne Asada, starting this week. Carne Asada is Chipotle's newest protein addition since it reintroduced chorizo in September 2018. The Mexican food chain said that the new steak option will be available at its restaurants nationwide from Thursday, September 19, 2019. Pizza Hut has partnered with Cheez-It to launch a new item to its menu - the Stuffed Cheez-It Pizza. The pizza chain, a subsidiary of Yum! Brands, said that the new item combines Pizza Hut pizza and the Cheez-It cheese snack. Stuffed Cheez-It Pizza will be available on Pizza Hut menus nationwide for a limited-time. Pizza Hut is the official pizza sponsor of the NFL and NCAA. The U.S. Food and Drug Administration on Tuesday unveiled a new international collaboration for simultaneous review and approval of cancer drugs along with the agency's Australian and Canadian counterparts. The simultaneous approval of cancer therapies by the three regulators is intended to accelerate the process of making these new treatments available to patients around the world.
Follow RTT